Source comparison
TB-500 vs BPC-157 vs GHK-Cu: Scar Healing Mechanism Comparison
Three peptides dominate research interest for wound healing and scar modulation: TB-500, BPC-157, and GHK-Cu. Each operates through distinct pathways. TB-500 (Thymosin Beta-4 Fragment) Actin polymerization regulation, fibroblast migration, VEGF upregulation Re
This comparison does not assign a generated winner or score.
- Three peptides dominate research interest for wound healing and scar modulation: TB-500, BPC-157, and GHK-Cu. Each operates through distinct pathways.
- TB-500 (Thymosin Beta-4 Fragment)
- Actin polymerization regulation, fibroblast migration, VEGF upregulation
- Reduces scar width and thickness during active healing phase; no effect on mature scars
- Subcutaneous injection 2–4 mg twice weekly
- Moderate. Animal models and in vitro studies; limited human clinical data
- Best evidence for organized collagen deposition and faster wound closure. Timing-dependent efficacy
- BPC-157 (Body Protection Compound)
- VEGF pathway activation, nitric oxide modulation, growth hormone receptor interaction
- Accelerates wound closure; unclear impact on final scar quality vs healing speed
- Subcutaneous or oral (gastric stability claimed) 200–500 mcg daily
- Limited. Primarily rodent studies; mechanism partially theoretical
- Strong angiogenesis promotion but less direct fibroblast regulation than TB-500; oral claims lack human bioavailability data
- GHK-Cu (Copper Peptide)
- Matrix metalloproteinase modulation, collagen synthesis regulation, antioxidant activity
- Stimulates remodeling of existing scar tissue through MMP activation; may reduce older scar density
- Topical application or subcutaneous injection 1–3 mg per application
- Moderate. Dermatology studies focus on skin regeneration and anti-aging; wound healing secondary
- Only peptide with evidence for remodeling established scars (via MMP-mediated collagen turnover); works on different timeline than TB-500
- TB-500 excels at influencing how tissue forms during the repair window. BPC-157 accelerates closure but with less data on scar architecture outcomes. GHK-Cu targets scar remodeling after formation through matrix metalloproteinase activation. A mechanism that can break down and reorganize existing collagen, making it the only option in this group with potential impact on mature scars. For optimal outcomes, some research protocols combine TB-500 during acute healing with GHK-Cu during the remodeling phase, though no controlled trials have tested this sequencing directly.